NCT04558320 is a clinical trial in Coronavirus Infection, sponsored by University of Rochester.

Who is sponsoring NCT04558320?

NCT04558320 is sponsored by University of Rochester.

What condition does NCT04558320 study?

NCT04558320 studies Coronavirus Infection.

Is NCT04558320 still recruiting?

NCT04558320 is currently completed. Last updated 4 November 2021.

Last reviewed 2021-11-04 · How we verify

NCT04558320

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 and Lactating Mothers

Completed Last updated 4 November 2021

What this trial tests

trial in Coronavirus Infection in 76 participants. Completed in 1 September 2021.

Timeline

2 July 2020

Primary endpoint
1 April 2021

1 September 2021

Quick facts

Lead sponsor	University of Rochester
Status	Completed
Study type	OBSERVATIONAL
Enrollment	76
Start date	2 July 2020
Primary completion	1 April 2021
Estimated completion	1 September 2021
Sites	1 location across United States

Conditions studied

Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

University of Rochester

Who can join

1 Day and older, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if there may be COVID-19 virus in various samples collected from mothers and infants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

NCT04885504 — Post COVID-19 Biorepository · recruiting
NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04558320 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 4 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04558320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing